French drugmaker Sanofi went public with a $9.3 billion offer to buy Medivation on Thursday, setting up what could be a lengthy takeover battle after the U.S. cancer firm rebuffed its approaches.
Sanofi could now face a prolonged takeover fight with other players potentially getting involved, including Japan's Astellas Pharma, Medivation's partner on its prostate cancer drug Xtandi. Britain's AstraZeneca has also been reported to have looked at Medivation.
Pour la première fois, des chercheurs viennent de démontrer qu'un organisme dépourvu de système nerveux est capable d'apprentissage. Une équipe du Centre de recherches sur la cognition animale (CNRS/Université Toulouse III – Paul Sabatier) a réussi à démontrer qu'un organisme unicellulaire, le protiste Physarum polycephalum, est capable d'une forme d'apprentissage nommée habituation. Cette découverte permet d'éclairer l'origine de la capacité d'apprentissage durant l'évolution, avant même l'apparition du système nerveux et du cerveau. Elle pourrait également amener à s'interroger sur la capacité d'apprentissage d'autres organismes extrêmement simples comme les virus et les bactéries. Ces résultats sont publiés dans la revue Proceedings of the Royal Society B le 27 avril 2016.
Today, scientists announced that, for the first time in history, gravitational waves have been detected.
Gravitational waves are ripples in spacetime throughout the universe. What’s truly remarkable about this discovery is that Albert Einstein predicted the existence of gravitational waves 100 years ago, but scientists have never been able to detect them, until now.
The discovery came out of the U.S. based Laser Interferometer Gravitational Wave Observatory (LIGO). The mission of LIGO was to directly measure gravitational waves. In order to do that, LIGO scientists needed to construct the most precise measuring device the world had ever seen.
The LIGO project, which began in 1992, was the largest scientific investment the National Science Foundation (NSF) has ever made.
At an NSF press conference this morning, LIGO Laboratory Executive Director, David Reitze, said “This was a scientific moon shot. And we did it – we landed on the moon.”
LIGO consists of two 4 kilometer (2.5 mile) tunnels located in Louisiana and the state of Washington. Because gravitational waves stretch space in one direction and compress space in the other, LIGO was designed to measure changes in length across large land distances. If they could detect a stretch of land in the LIGO tunnels in one direction and compression in the other, they could theoretically detect a gravitational wave.
The “ruler” that scientists used to measure these tunnel lengths was the speed of light. The speed of light is constant, so LIGO can determine the length of the tunnels by measuring the time it takes for a laser to bounce from one end of the tunnel to the other.
Gravitational waves are created when masses accelerate. Measured back on September 14th, 2015, the gravitational wave signal that the LIGO scientists detected matches the exact signal they’d expect from two merging black holes accelerating at half the speed of light.
Reitze explained that the black holes that created this gravitational wave merged 1.3 billion years ago. It took that long for the wave to travel to the Earth. Each of the black holes were 30 times the mass of the sun and were accelerating at half the speed of light when they collided into each other. The ability to measure gravitational waves will open up an entirely new window for astronomy. Reitze explained that this will enable scientists to look at the universe in a new way.
Translating new cell-based therapies to the clinic for patients with neurodegenerative disorders is complex. It involves pre-clinical testing of the cellular product and discussions with several regulatory agencies, as well as ethical debates. In an attempt to support efforts around the world, we set up a global consortium that brings together the major funded teams working on developing a stem cell-derived neural transplantation therapy for Parkinson’s disease (PD). This consortium, G-Force PD, involves teams from Europe, USA, and Japan, and has already met on two occasions to discuss common problems, solutions, and the roadmap to the clinic. In this short review, we lay out the brief history and rationale for this initiative and discuss some of the issues that arose in our most recent meeting (May 2015) as we consider undertaking first-in-human clinical trials with stem cell-derived neurons for PD.
This is The 6th Annual Personalized and Precision Medicine Conference Agenda. The conference will be exploring the ways in which Personalized & Precision Medicine is reshaping healthcare. This conference brings together multiple stakeholders, including payers, molecular diagnostics companies, genome analysis/interpretation companies, clinicians and many others in order to provide attendees with a holistic view of the personalized medicine landscape.
Le groupe chimique et pharmaceutique allemand Bayer a fait une offre non sollicitée de 62 milliards de dollars américains pour acquérir le spécialiste américain des semences génétiquement modifiées Monsanto, afin de créer un leader mondial de l'agrochimie.
Paris and Tarrytown, New York - September 28, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc.announced today that the European Commission (EC) has granted marketing authorization for Praluent®(alirocumab) for the treatment of bad cholesterol, known as low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia. Praluent is the only EC-approved PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor that is available in two starting doses as a single 1-milliter (mL) injection (75 mg and 150 mg) once every two weeks, offering two levels of efficacy. Praluent will be available in a single-dose pre-filled pen that patients self-administer.
The EC marketing authorization is based on data from 10 pivotal Phase 3 ODYSSEY trials, including five placebo-controlled and five ezetimibe-controlled. The data showed consistent, robust reductions in LDL-cholesterol for Praluent compared to placebo or ezetimibe, when added to current standard-of-care, which included maximally-tolerated statins. All trials met their primary efficacy endpoint, demonstrating significantly greater reductions from baseline in LDL-cholesterol at week 24, compared to placebo or ezetimibe. In the placebo-controlled trials, the average LDL-cholesterol reductions from baseline at week 24 for the Praluent group ranged from 46 to 61 percent. In the ezetimibe-controlled trial with Praluent added to background statins, the average change in LDL-cholesterol from baseline was 51 percent at week 24. In the ezetimibe trials with patients not on statins, the average LDL-cholesterol reduction from baseline in the Praluent group ranged from 45 to 47 percent at week 24. Additionally, significantly more patients achieved an LDL-cholesterol level of less than 70 mg/dL (<1.81 mmol/L) in the Praluent group compared to placebo or ezetimibe at week 12 and week 24.
A cut or torn tire usually means one thing—you have to buy a new one. But some day, that could change. For the first time, scientists have made tire-grade rubber without the processing step—vulcanization—that has been essential to inflatable tires since their invention. The resulting material heals itself and could potentially withstand the long-term pressures of driving. Their report appears in the journal ACS Applied Materials & Interfaces.
Vulcanization involves adding sulfur or other curatives to make rubber more durable while maintaining its elasticity. But once an errant piece of glass or other sharp object pierces a tire, it can't be patched for long-term use. Researchers are beginning to develop self-healing rubber in the laboratory, but these prototypes might not be stable over time either. Amit Das and colleagues wanted to address that shortcoming.
Using a new simple process that avoids vulcanization altogether, the researchers chemically modified commercial rubber into a durable, elastic material that can fix itself over time. Testing showed that a cut in the material healed at room temperature, a property that could allow a tire to mend itself while parked. And after 8 days, the rubber could withstand a stress of 754 pounds per square inch. Heating it to 212 degrees Fahrenheit for the first 10 minutes accelerated the repair process. The researchers say their product could be further strengthened by adding reinforcing agents such as silica or carbon black.
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.